Pancreatic neuroendocrine tumors and their hepatic metastases have an inconsistent appearance with only a small percentage of lesions appearing as cystic masses in computed tomography (CT) and magnetic resonance imaging (MRI). They can therefore be mistaken for benign or infectious lesions, leading to a false diagnosis with delayed or inadequate treatments. We reported a patient with an upper abdominal pain that lasted for several months, caused by a huge cystic neuroendocrine carcinoma of the liver that was mistakenly interpreted as a complicated or hydatid cyst. We presented the findings of the initial CT and the subsequently performed MRI under the application of hepatocyte specific contrast material, which led to distinct differential diagnoses that had a major impact on the therapeutic strategy.

A 50-year-old male patient complained of an epigastric pain that he was having for a week. Hematology laboratory data were within the normal range. Contrast enhanced CT from an external institution showed a 15 mm hypodense mass in the head of the pancreas when compared with the uninvolved pancreas (Fig. 1A). The pancreatic mass was interpreted as ductal adenocarcinoma or neuroendocrine tumor. Additionally, a CT scan showed a 10 cm hypodense mass in the right hepatic lobe with internal thin septa (Fig. 1D), and this was interpreted as a simple cyst of the right hepatic lobe. The patient was referred to our center for surgical therapy. At our center, for further preoperative evaluation, MRI of the liver was performed with unenhanced T1- and T2-weighted images with fat suppression, contrast enhanced sequences using Gd-EOB-DTPA (Primovist, Bayer Schering Pharma, Berlin, Germany) with early dynamic acquisition, and delayed imaging in the hepatobiliary phase after 20 minutes (1.5 T; AVANTO; Siemens Medical Systems, Erlangen, Germany). On T1-weighted MR image, pancreatic mass showed hypointensity compared with the uninvolved pancreas (Fig. 1B). T1-weighted image after application of Gd-EOB-DTPA shows subtle enhancement of the mass in the arterial phase (Fig. 1C).

On MRI, the lesion in the right liver lobe, measuring 10.0 × 6.0 cm, showed a thin wall and septa. On T1-weighted transverse gradient echo sequences, the wall and septa appeared hypointense, while the liquid content showed subtle hyperintensity (Fig. 1E). On T2-weighted transverse turbo spin echo sequences, the wall and septa were hyperintense, while the liquid content showed subtle hyperintensity (Fig. 1F). On T1-weighted image with contrast enhancement, no Gd-EOB-DTPA uptake is present in wall and septations of the mass, while the cyst content remained hypointense (Fig. 1G). Based on these findings, a complicated or hydatid cystic tumor was preferred as the differential diagnosis.

Pancreatectomy and a right hemihepatectomy (Segments VI-VII) were performed. Resected pancreatic specimen shows irregular, margined, and yellowish tumor in the head of the pancreas, measuring 2.3 × 1.5 × 1.2 cm, without common bile duct invasion (Fig. 1H). Resected hepatic specimen shows the large liver mass possessing a capsule, containing hemorrhages (Fig. 1I). Histology of the pancreatic tumor reveals tumor cells featuring abundant cytoplasm andprominent nucleoli; frequent mitotic rate shows the organoid, nesting, trabecular, and palisading pattern (Fig. 1J). Hepatic tumor shows similar histologic features with the pancreatic mass, and partially cystic neoplasm infiltrates the adjacent liver parenchyma with microcystic and trabecular growth pattern (Fig. 1K). There was an expression of CK7, synaptophysin, chromogranin, and CK20 (Fig. 1L). These findings resulted in the diagnosis of a well differentiated neuroendocrine tumor of pancreatic origin with hepatic metastasis (1).

Pancreatic neuroendocrine tumors (PNETs) are rare neoplasms that affect only 1 in 300000 individuals in the United States annually, and comprise 1% to 2% of all pancreatic tumors (1, 2). The major categories of gastroenteropancreatic neuroendocrine tumors defined by the WHO are well-differentiated neuroendocrine tumors, which show benign behavior or uncertain malignant potential, well-differentiated neuroendocrine carcinomas, which are characterized by low-grade malignancy, and poorly differentiated (usually small cell) neuroendocrine carcinomas of high-grade malignancy (3).

Most malignant PNETs metastasize to the liver where they derive their blood supply from hepatic artery branches (75-80%) (4). Hepatic metastasis occurs in 30-85% of PNETs, and is potentially and completely resectable only in 7-15% of the patients (5, 6). Because of the varying presentation of the patients with metastatic hepatic neuroendocrine tumors and the rarity of this disease, it is often difficult to define the ideal treatment approach based upon the current literatures. In patients with isolated hepatic diseases, an increasing number of published findings report the improved survival rates in the patients undergoing complete resection (6).

Hepatic metastases are most frequently hypointense or isointense compared to the surrounding normal liver parenchyma on T1-weighted image, and are hyperintense on T2-weighted images. On dynamic gadolinium enhancement phases, metastases typically showed early enhancement (7). Cystic appearance of neuroendocrine carcinoma (NEC) metastases is rare. The low prevalence of NEC and the unusual, large solitary cystic lesion in the liver made this differential diagnosis quite unlikely, which initially resulted in the interpretation as an echinococcal cyst based on the monophasic contrast enhanced CT (8). Despite newer chemotherapeutic and immunologic agents, surgical therapy remains the most efficient approach to metastatic disease and offers the longest lasting benefits. Surgical debulking of the hepatic disease improves the chance of survival (9).

In this article, we described the CT and MRI findings on cystic appearance of hepatic metastases from PNETs, which was mistakenly interpreted as complicated or hydatid cyst. Because of variability of neuroendocrine tumor appearance in imaging, percutaneous biopsy should be considered for atypical imaging to avoid delayed diagnosis and wrong treatment.